GSE128730 neratinib OVCAR-8 7 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE128730_neratinib_OVCAR-8_7_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE128730_neratinib_OVCAR-8_7_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE128730_neratinib_OVCAR-8_7_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE128730_neratinib_OVCAR-8_7_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

ribosomal protein S4 Y-linked 1

Gene

carbonic anhydrase 2

Gene

S100 calcium binding protein A9

Gene

microtubule associated protein 7

Gene

lysine demethylase 5D

Gene

aquaporin 3 (Gill blood group)

Gene

secreted frizzled related protein 1

Gene

activating transcription factor 3

Gene

inhibitor of DNA binding 1

Gene

tumor associated calcium signal transducer 2

  • Gene

    ribosomal protein S4 Y-linked 1


  • Gene

    carbonic anhydrase 2


  • Gene

    S100 calcium binding protein A9


  • Gene

    microtubule associated protein 7


  • Gene

    lysine demethylase 5D


  • Gene

    aquaporin 3 (Gill blood group)


  • Gene

    secreted frizzled related protein 1


  • Gene

    activating transcription factor 3


  • Gene

    inhibitor of DNA binding 1


  • Gene

    tumor associated calcium signal transducer 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.